BMO Considers Recent Sales Data on Arena's Belviq, Maintains Market Perform Rating

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Investors in shares of Arena Pharma (NASDAQ: ARNA) are responding to several news items Monday. The stock last traded at $6.30, down more than 1.5 percent from Friday's closing price.In addition to an earlier Seeking Alpha article evaluating the company's Belviq sales after three months, traders are also digesting a research note from BMO's Jim Birchenough. Birchenough said 13-week prescriptions from Belviq showed 0.2 percent week-over-week growth. For the week ended Aug. 30th, the BMO analyst said total scrips were 3,849. Birchenough compared these figures to data on VIVUS's (NASDAQ: VVUS) Qsymia which showed units of 1,457 over the same duration.Birchenough iterated he would suggest investors wait on the sidelines regarding Arena.BMO maintains a Market Perform rating and $8 price target on shares of Arena.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!